Operational Lessons from Global Nephrology Trials
From novel drug targets for chronic kidney disease (CKD)[i] to advances in multifunctional drugs promising better efficacy, recent developments in…
Partner Content
-
-
The definitive infrastructure for modern drug development
Paradigm Health delivers a unified, AI-powered clinical research platform embedded within a national network of community and academic sites. By…
-
The future of quality in CDMOs: The five-stage journey to an advanced Pharmaceutical Quality System (PQS)
In the first part of our Q&A with Grace Breen, SVP, Quality, Sharp, we explored valuable insights derived from her…
-
Four ways to build a secure and scalable CGT distribution network
CGTs offer potentially life-changing treatment for a broad spectrum of complex diseases, from genetic conditions to cancers. The pace of…
-
Advancing pressure protection in biopharma: how integrated bypass technology elevates single-use pump design
In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process integrity and operator safety.…
-
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Oncology drug development has shifted decisively towards precision immunotherapies, where biomarker-defined patient populations play a pivotal role. Immuno-oncology now represents…
-
Why Timelines Break Down in Rare Kidney Drug Development
Enrollment challenges continue to be a defining constraint in nephrology research. In a January 2026 snapshot of GlobalData’s clinical trial…
-
The hidden bottleneck in digital healthcare: Why hospital wireless networks are under pressure in 2026
Healthcare is entering a new era of digital transformation. In the US, competition among leading providers is driving rapid adoption…
-
The evolving landscape of subcutaneous drug administration
In pharmaceutical development, several major trends are shaping the future of drug delivery. For decades now, the industry has been…
-
CGT’s next obstacle: Securing the leukapheresis supply chain
Clinical trial numbers for CAR-T therapies have risen dramatically in recent years, and as these programmes expand beyond oncology into…